On June 4, MiNT Technology-P (07666.HK) declined 5.22% in regular trading, trading at 14.94 HKD/share, with trading volume of 6.7892 million HKD. The stock continues its post-IPO correction trend after surging 173% on its May 13 listing debut.

On the news front, the sustained pullback is driven by multiple factors. As the world's first AI-powered drug delivery company to list on HKEX at an IPO price of 10.50 HKD, the stock has retreated significantly from its first-day highs. Part of the international placement shares carry no lock-up period, creating persistent profit-taking pressure. The company remains in early-stage commercialization with cumulative losses of approximately 1.5 billion RMB over the past three years and volatile revenue, leaving growth prospects yet to be proven.

Although the company recently announced a strategic alliance with Deerfield Management to co-develop AI-driven protein therapeutics and in-vivo immunotherapies, and launched its AiProtein platform, the fading new-stock momentum continues to weigh on share price performance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)